Amgen wins orphan drug designation from FDA for Xgeva; Pfizer settles Parkinson's drug claims with some Australian plaintiffs;

@FiercePharma: Top-read pharma news this weekend: With Pfizer on the loose, traders worry Actavis-Allergan M&A saga isn't over yet. Article | Follow @FiercePharma

@EricPFierce: ICYMI: Sanofi, Viehbacher accused of kickback scheme in whistleblower suit. More | Follow @EricPFierce

@CarlyHFierce: ICYMI: Long-acting Copaxone to launch early next year in Europe, Teva says. Story | Follow @CarlyHFierce

> The FDA granted Amgen ($AMGN) orphan drug designation for Xgeva, a treatment for hypercalcemia of malignancy, a serious complication in patients with advanced cancer. Release

> Pfizer ($PFE) settled claims with 160 Australian plaintiffs who alleged that the company's drugs for Parkinson's disease caused gambling and hypersexual behavior. Story

> India's antitrust watchdogs cleared Sun Pharmaceutical's $3.2 billion deal to buy fellow Indian drugmaker Ranbaxy Laboratories pending product divestitures. Story

> Novo Nordisk ($NVO) revealed promising Phase III study data for its Novoeight treatment for hemophilia A at the 56th Annual Meeting of the American Society of Hematology. More

Medical Device News

@FierceMedDev: Physicians weigh in on ventricular assist devices for treating heart failure. Story | Follow @FierceMedDev

@EmilyWFierce: AstraZeneca scores a victory in pay-for-delay Nexium case. Article | Follow @EmilyWFierce

> J&J gains FDA clearance for rare pediatric spinal device. More

> National Cancer Institute backs startup's hazardous drug containment device. Story

> BlackBerry, NantHealth to launch HIPAA secure smartphone genome browser. News

Biotech News

@FierceBiotech: Merck splashes into antibiotics with $9.5B Cubist deal. Story | Follow @FierceBiotech

@JohnCFierce: Agios' AG-221 racks up more cancer remissions, setting the stage for a pivotal challenge. Article | Follow @JohnCFierce

@DamianFierce: Sun Pharma has a nuanced approach to Twitter. More | Follow @DamianFierce

> Six years and $8.8B later, Takeda is ditching the Millennium name. Item

> Merck's PD-1 star Keytruda shines at ASH, but lags behind Bristol-Myers' rival. Article

> Panel: How to understand the long biotech boom? Editor's Corner

CRO News

> WuXi moves to list a subsidiary on the Chinese market. More

> Recipharm cues job cuts as a long-time partner drops out. Report

> Catalent signs on to help Sellas get a repurposed drug to the finish line. Article

> INC Research lends its weight to trial site advocacy group. Item

> EU nations yank drugs over GVK data scandal. Story

Biotech IT News

> Hackers use Wall Street know-how to steal stock-moving biotech info. More

> Flatiron Health teams with Foundation Medicine to develop oncology platform. Report

> Ex-Pfizer SVP named CEO of BioClinica. Item

> Documents reveal FDA's use of computer forensics to uncover data falsification. Story

> 23andMe gets regulatory thumbs-up to sell DNA tests in U.K. Article

Animal Health News

> Kindred shares plummet as company nixes atopic dermatitis drug. Report

> Newly sequenced ferret genome reveals clues to human lung diseases. More

> Report: New FDA policy on animal antibiotics has loopholes. Item

> Eco Animal Health doubles pretax profit as it expands into North America. Story

> Nexvet partners with Virbac for ex-U.S. sales of canine osteoarthritis drug. Article

And Finally… Roche ($RHHBY) is close to selecting a prospective buyer for its campus in North Jersey, sources say. The Swiss drugmaker announced in 2012 that it would leave the site after 80 years and hopes to find a buyer by the end of 2015. More

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.